Shanghai Pharmaceutical announced that recently, its subsidiary Changzhou Pharmaceutical Factory received a “Drug Registration Certificate” for rosofastatin ezetimib tablets issued by the State Drug Administration and approved the production of the drug. As of the announcement date, the company has invested about 9.68 million yuan in R&D expenses for this drug. In 2025, hospitals in mainland China purchased the drug for 25.72 million yuan. Approved production is beneficial to expanding market share and improving competitiveness. It also accumulates experience for subsequent generic drug declarations, but due to policy, market and other factors, sales did not meet expectations.

Shanghai Pharmaceutical announced that recently, its subsidiary Changzhou Pharmaceutical Factory received a “Drug Registration Certificate” for rosofastatin ezetimib tablets issued by the State Drug Administration and approved the production of the drug. As of the announcement date, the company has invested about 9.68 million yuan in R&D expenses for this drug. In 2025, hospitals in mainland China purchased the drug for 25.72 million yuan. Approved production is beneficial to expanding market share and improving competitiveness. It also accumulates experience for subsequent generic drug declarations, but due to policy, market and other factors, sales did not meet expectations.